Download Files:

(S)-Ro 32-0432

$850

Only 1000 item(s) left in stock.

Products Details

Product Description

– (S)-Ro 32-0432 is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC50 values of (S)-Ro 32-0432 for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research[1][2].

Web ID

– HY-108601A

Shipping

– Room temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C28H29ClN4O2

References

– [1]A M Birchall, et al. Ro 32-0432, a Selective and Orally Active Inhibitor of Protein Kinase C Prevents T-cell Activation. J Pharmacol Exp Ther. 1994 Feb;268(2):922-9.|[2]Thakur Gurjeet Singh, et al. Ro 32-0432 Attenuates Mecamylamine-Precipitated Nicotine Withdrawal Syndrome in Mice. Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):197-204.

CAS Number

– 1781828-85-0

Molecular Weight

– 489.01

SMILES

– O=C(C(C1=C(C[C@@H](CN(C)C)CC2)N2C3=C1C=CC=C3)=C4C5=CN(C)C6=C5C=CC=C6)NC4=O.[H]Cl

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Neurological Disease

Solubility

– 10 mM in DMSO

Target

– PKC

Isoform

– PKCα;PKCβ;PKCγ;PKCε

Pathway

– Epigenetics;TGF-beta/Smad

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.